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Next generation sequencing studies in chronic lymphocytic leukemia(CLL) have revealed novel genetic variants that have been associat-ed with disease characteristics and outcome. The aim of this study
was to evaluate the prognostic value of recurrent molecular abnormalities
in patients with CLL. Therefore, we assessed their incidences and associa-
tions with other clinical and genetic markers in the prospective multicenter
COMPLEMENT1 trial [treatment naive patients not eligible for intensive
treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL 
(O-CHL)]. Baseline samples were available from 383 patients (85.6%) rep-
resentative of the total trial cohort. Mutations were analyzed by amplicon-
based targeted next generation sequencing (tNGS). In 52.2% of patients we
found at least one mutation; the incidence was highest in NOTCH1
(17.0%), followed by SF3B1 (14.1%), ATM (11.7%), TP53 (10.2%), POT1
(7.0%), RPS15 (4.4%), FBXW7 (3.4%), MYD88 (2.6%), and BIRC3 (2.3%).
While most mutations lacked prognostic significance, TP53 (HR2.02,
P<0.01), SF3B1 (HR1.66, P=0.01), and NOTCH1 (HR1.39, P=0.03) were
associated with inferior progression-free survival (PFS) in univariate analy-
sis. Multivariate analysis confirmed the independent prognostic role of
TP53 for PFS (HR1.71, P=0.04) and overall survival (OS) (HR2.78, P=0.02),
and of SF3B1 for PFS only (HR1.52, P=0.02). Notably, NOTCH1 mutation
status separates patients with a strong from those with a weak benefit from
addition of ofatumumab to CHL (NOTCH1wt: HR0.50, P<0.01;
NOTCH1mut: HR0.81, P=0.45). In summary, TP53 and SF3B1 were con-
firmed as independent prognostic factors and NOTCH1 as a predictive fac-
tor for reduced ofatumumab efficacy in a randomized chemo/immunother-
apy CLL trial. These results validate NGS-based mutation analysis in a mul-
ticenter trial and provide a basis for expanding molecular testing in the
prognostic workup of patients with CLL. (Trial registered at clinicaltrials.gov
identifier: NCT00748189.)
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) is a heterogeneous
disease. Many prognostic factors have been identified in
the last decades, but only a few have found their way into
clinical practice.1 In a variety of different CLL trials,
genomic aberrations, particularly 17p deletion and muta-
tion status for TP532-7 had the strongest relation to clinical
outcome. Their assessment before institution of therapy
has therefore been recommended for every CLL patient.1
The availability of new CLL treatment modalities have
raised the question of the influence of these genomic aber-
rations as predictive factors for treatment response.
Recent insights from unbiased next generation sequenc-
ing (NGS) approaches describe more than 40 recurrently
mutated cancer driver genes in CLL, the clinical signifi-
cance of which often remains undefined.8-11 The clinical
value of single mutations was mostly studied in heteroge-
neous patient cohorts and assessed outside of the context
of clinical and biologic features.12-16 Therefore, there is a
need to perform mutation screening in large clinical trials,
as they provide a homogeneous cohort of patients, stan-
dardized assessment of clinical and laboratory parameters,
and valid outcome data. The UK CLL4 trial and the
GCLLSG CLL8 trials served to determine the prognostic
impact of recurrent mutations among the minority of
young/fit patients. Both cohorts were screened for muta-
tions in TP53, NOTCH1 and SF3B1, as mutations in these
genes have a high incidence (10-15%) and typically occur
in hotspots, which allows the use of Sanger sequencing for
mutation screening. While mutated TP53 (TP53mut) was
validated as an independent prognostic factor for progres-
sion-free survival (PFS) and overall survival (OS) in both
studies, results for the other genes were less clear: mutated
SF3B1 (SF3B1mut) was associated with decreased PFS in
CLL8 and decreased OS in UK CLL4 but not vice
versa.12,13,17 Notably, and in contrast to previous reports,
mutated NOTCH1 (NOTCH1mut)  was not an independent
prognostic factor for PFS in both trials, but was identified
as predicting the lack of efficacy of the addition of CD20
antibody (rituximab) in the CLL8 trial;13 this provocative
finding needs confirmation in additional data sets. 
The COMPLEMENT1 trial evaluated chlorambucil
(CHL), a less intense chemotherapy backbone for which
the majority of CLL patients are eligible, with or without
the addition of the CD20 antibody ofatumumab.15,16
Ofatumumab binds to a different epitope of CD20 com-
pared to rituximab and is more efficacious in triggering
complement-dependent cytotoxicity (CDC) in vitro. The
major result of COMPLEMENT1 was a significantly pro-
longed PFS by the addition of ofatumumab (22.4 months;
95%CI: 19.0-25.2) to chlorambucil18,19 (13.1 months;
95%CI: 10.6-13.8) in a population who cannot tolerate
more intensive therapy. The well characterized patient
cohort and mature follow up of COMPLEMENT1 provided
an ideal background to study incidence, associations, and
prognostic as well as the predictive value of gene mutations
in a typical, elderly, front-line CLL patient population. 
Methods
Patients 
The GlaxoSmithKline-sponsored phase III trial COMPLE-
MENT1 (OMB110911) enrolled 447 untreated patients ineligible
for fludarabine-based therapy and in need of treatment. Subjects
were randomly assigned to receive CHL or O-CHL with a ratio
of 1:1. The primary study end point was PFS as determined by
an independent review committee. Biomarker analysis was
implemented in the study protocol and was approved by the
institutional review board or ethics committee of each partici-
pating institution. Each patient provided written informed con-
sent before enrolment. For 383 of 447 patients (85.7%), a base-
line sample with sufficient DNA and informed consent for
research purposes were available. This subset was representa-
tive of the intent-to-treat population with regard to clinical, lab-
oratory and genetic baseline characteristics (Online
Supplementary Table S1). 
Sequencing
We designed a customized Illumina™ Truseq amplicon panel
for all coding regions of TP53, ATM, BIRC3, MYD88, FBXW7,
POT1, and for the most commonly affected exons 14, 15, 16 and
18 in SF3B1 and exon 34 in NOTCH1. The cumulative target
size was 24,161 basepairs (bp) covered by 221 amplicons with a
length of up to 250 bp each. Adjacent 10 intron bp were included
to cover splice site mutations. Input of 250 ng DNA from periph-
eral blood mononuclear cells isolated by Ficoll gradient centrifu-
gation were sufficient for libraries according to the Illumina
TruSeq Custom Amplicon (TSCA) protocol. Sequencing was
performed on an Illumina MiSeq™ with the 500-cycle MiSeq
Reagent Kit v2. Mutations in the 3’UTR of NOTCH1 and in
RPS15 exon 4 were analyzed via Sanger sequencing.
Statistical analysis
Statistical analyses were performed on an intent-to-treat basis
including all patients with samples available. Analysis was per-
formed using R studio 1.1.447 with survival package (RStudio
Inc., Boston, MA, USA).  Categorical variables were compared
using the Fisher Exact test, and continuous variables were com-
pared using non-parametric rank-sum tests. Statistical tests were
two-sided; P<0.05 was considered statistically significant. There
were no adjustments for multiple testing, so that all reported P-
values have an exploratory character for all analysis except for
Online Supplementary Figure S2 for which we used false discovery
rate (FDR) as an adjustment. 
Time to event was analyzed by Kaplan-Meier estimates and
log-rank. To identify independent prognostic factors, we includ-
ed treatment arm, del11q, del17p and IGHV mutation status as
factors associated with PFS in univariate analysis in addition to
all genetic subgroups defined by gene mutations. These 13
parameters were tested in 383 patients without forward or back-
ward selection procedures to explore the independent prognos-
tic character. In addition, we performed a multivariate treat-
ment-gene mutation interaction analysis to explore treatment
dependent and therefore predictive value. We used R studio
1.1.447 (RStudio Inc., Boston, MA, USA) with survival package
for all statistical analyses.
Results
Spectrum and associations of mutations 
Sequencing of 383 patient samples resulted in a mean
coverage of 2,852 reads and 98.2% of target reads above
100x. We identified a total of 304 mutations in the select-
ed gene set. Mutation incidences were NOTCH1 (17.0%),
SF3B1 (14.1%), ATM (11.7%), TP53 (10.2%), POT1
(7.0%), RPS15 (4.4%), FBXW7 (3.4%), MYD88 (2.6%),
and BIRC3 (2.3%) (Figure 1A). When looking at the muta-
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tion type, we observed 195 missense mutations, 3 inser-
tions, 56 deletions, 27 nonsense mutations, 11 splice site
and 12 3’UTR mutations. Of all variants, 122 were select-
ed for validation via Sanger sequencing and all of them
were confirmed, so that further validation procedures
were omitted (Online Supplementary Table S2). While the
number of mutations was slightly higher in CHL versus
O-CHL (178 vs. 126, not significant), the number of
patients with at least one mutation was similar in both
arms: 55% for CHL and 53% for O-CHL (see Online
Supplementary Figure S1 for a detailed overview). In the
total cohort, only 11.5% of patients had neither a muta-
tion nor a chromosomal aberration in the analyzed tar-
gets. As previously reported, mutations in SF3B1 and
MYD88were exclusively single nucleotide variants (SNV).
Of 66 NOTCH1 mutations, 52 caused stop codons via
frameshift or nonsense mutation and 12 affected the
3’UTR (Online Supplementary Table S2). TP53 and BIRC3
showed various patterns of mutations including inser-
tions, deletions and exonic as well as splice site SNV.
Regarding associations, all but one case with MYD88
mutation had mutated IGHV, while TP53, RPS15 and
BIRC3 mutations were found predominantly in patients
with unmutated IGHV (Figure 1). As to cytogenetics, we
found deletion of 11q associated with mutations of ATM
and BIRC3 and trisomy 12q associated with mutations in
NOTCH1, BIRC3 and FBXW7. Interestingly, of the nine
BIRC3 mutated cases, six had an aberration in 11q and
four in 12q. As expected, high concordance was found
between 17p deletion and mutation in TP53, but also with
FBXW7mut. These associations hold true when considering
correction for multiple testing with false discovery rate
(Online Supplementary Figure S2).
Analyzing mutations in nine different genes and corre-
lation with genomic aberrations and IGHV mutation sta-
tus allowed us to derive an interaction network based on
significant correlations considering incidence, co-occur-
rence, or mutual exclusivity (Figure 2). Interestingly, two
dichotomies emerge from the complex network. Firstly,
there is a mutual exclusivity between del13q and +12q.
While del13q does not significantly associate with any of
the gene mutations, cases with +12q cluster with mutated
NOTCH1, BIRC3 and FBXW7. The second dichotomy is
found in mutation of TP53 and del17p on one side and a
cluster including del11q, +12q and ATM on the other side.
Interestingly, mutations of SF3B1 are not associated with
either group, suggesting that these mutations represent an
independent pathogenic mechanism. Concerning clinical
associations, SF3B1 mutations were more common in
male patients (Online Supplementary Table S3) and associat-
ed with high absolute lymphocyte count (ALC) and
CD19+CD5+ fraction by flow cytometry (P<0.01 and
E. Tausch et al.
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Figure 1. Incidence and distribution of genetic parameters (gene mutations, genomic aberrations and IGHV status). (A) Cluster diagram of patients (columns) with
data for all genetic parameters (rows) (right) and overall incidence (left). Distribution of markers is ordered by rows. (B) Circos plots of the co-occurrence of gene
mutations with each other (left) and pairwise with chromosomal aberrations (right). Lengths of arcs correspond to total incidences of respective markers while the




P=0.03), whereas ALC in MYD88 mutated patients was
low. WBC >50x109/L were found more often in patients
with mutated TP53, RPS15 or ATM (P=0.05, P=0.02 and
P=0.03, respectively).
Clinical outcome and prognostic impact of gene 
mutations in the full cohort
A significantly lower overall response rate was found
only for TP53mutated cases (HR 5.20, P<0.01). In univari-
ate analysis, significantly decreased PFS was found for
patients with mutations in TP53 (HR 2.02, P<0.01), SF3B1
(HR 1.66, P<0.01), and NOTCH1 (HR 1.39, P=0.03), but
not for patients with mutations in ATM (HR 1.16, P=0.42)
or BIRC3 (HR 1.63, P=0.23) (Table 1 with 95%CI, Figure
3, and Online Supplementary Figure S3). OS was significant-
ly shorter in patients with mutations of TP53, and this
was observed both in the total cohort (HR 4.25, P<0.01) as
well as in patients without deletion of 17p (HR 2.56,
P=0.03) (data not shown). Remarkably, no death event was
observed among MYD88 mutated patients. The number
of mutated genes correlated with PFS, and patients harbor-
ing two or more mutated genes had shorter PFS (Online
Supplementary Figure S4). Mutation in at least one of the
target genes associated with significantly shorter OS,
while the number of mutated genes did not play a signifi-
cant role. 
Taking into account that a disruption of both alleles of
BIRC3 or ATM could be required to observe any effect as
described in the UK CLL420 trial, we considered the del11q
status for the impact of mutations in both genes.
However, in our patient cohort, mutation of ATM did not
add significant prognostic value either in the 11q deleted
subgroup or in the 11q disomic subgroup (Online
Supplementary Figure S5). As BIRC3 was mutated in only
nine patients, the subgroups were too small to address this
question. 
Mutations in TP53 and ATM showed high variant allelic
fractions (VAF) of the mutant allele, mainly explained by a
high co-occurrence with deletion of the other allele
(Online Supplementary Figure S6A). Also mutations with a
variant allele fraction (VAF) ≤10%, usually undetectable
by Sanger sequencing, were rare in TP53 (2 of 38) and
absent in MYD88 in this trial, but present in a significant
proportion of cases with mutation of SF3B1, NOTCH1 or
FBXW7. As the role of mutations with minor allelic frac-
tion is still unclear, we performed survival analyses includ-
ing patients with wild-type (WT) SF3B1/NOTCH1 and
with major and minor (< 10% VAF) mutated fractions
(only NGS data considered). Interestingly, patients affect-
ed by only minor SF3B1 mutated clones showed signifi-
cantly shorter PFS in comparison to WT (HR 3.09, 95%CI:
0.67-14.30, P=0.01), while for NOTCH1, minor mutations
had no significant impact on the full cohort, mainly due to
low numbers (HR 1.54, 95%CI: 0.71-3.34, P=0.26) (Online
Supplementary Figure S6B and C).
We performed multivariable analyses including treat-
ment arm, IGHV mutation status, del17p, del11q and gene
mutations to examine the independent prognostic value of
these parameters. Besides ofatumumab+chlorambucil,
IGHV status, del17p and del11q, only mutations of TP53
(HR 1.71, P=0.04) and SF3B1 (HR 1.52, P=0.02) were iden-
tified as independent factors associated with decreased
PFS. For OS, only presence of del17p and TP53 mutation
(HR 2.78, P=0.02) retained a significant independent role
(Table 2 with 95%CI).    
Predictive value for the efficacy of ofatumumab 
addition
Randomization of patients into treatment arms with
and without ofatumumab allowed the evaluation of dif-
ferential CD20 antibody efficacy in subgroups defined by
mutations. In the total cohort of 383 patients, treatment
with ofatumumab was beneficial with regard to PFS (HR
0.53, P<0.01) as published for the whole trial population.19
Analyses of both treatment arms separately generally reit-
erated the results obtained for the total cohort, with muta-
tions in SF3B1 and TP53 being associated with shorter
PFS. However, for NOTCH1, we observed an impact on
PFS in the O-CHL treatment arm (HR 1.94, 95%CI: 1.25-
3.92, P<0.01) but not with CHL alone (HR 1.01, 95%CI:
0.69-1.47, P=0.98) (Figure 4). Conversely, the addition of
ofatumumab to chlorambucil in patients with NOTCH1wt
status was strongly beneficial (mPFS 23.8 vs. 13.3 months,
HR 0.50, 95%CI: 0.39-0.63, P<0.01), while the benefit in
the NOTCH1mut group was not significant (17.2 vs. 13.1
months, HR 0.81, 95%CI: 0.50-1.31, P=0.45). Notably, the
same analysis confirmed the addition of ofatumumab to
be beneficial in SF3B1 and TP53 mutated subgroups (for
SF3B1: mPFS 17.3 vs. 10.8 months, HR 0.53, 95%CI: 0.29-
0.97, P=0.03; for TP53: mPFS 12.8 vs. 3.7 months, HR 0.49,
95%CI: 0.23-1.05, P=0.05). This impact was strongest
with NOTCH1 mutations at a mutant allele fraction
>40% and weaker with smaller NOTCH1 variant fraction
(Online Supplementary Figure S7). To investigate the rela-
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Table 1. Prognostic associations of gene mutations and progression-free survival (PFS) / overall survival (OS) in the full trial cohort (both treat-
ment arms combined) in univariate analysis (log rank test).                         
                                                                   PFS                                                                               OS                         
Gene mutation                 HR                     95%CI                       P                        HR                    95%CI                     P                 N (events PFS/OS)
TP53                                       2.02                       1.18-3.45                     <0.01                        4.25                     1.65-10.92                  <0.01                        39 (27/16)
NOTCH1                                1.39                       1.04-1.86                       0.03                          0.84                      0.49-1.44                      0.62                           65 (50/10)
SF3B1                                     1.66                       1.12-2.47                     <0.01                        1.39                      0.67-2.87                      0.32                           54 (43/11)
ATM                                        1.16                       0.84-1.60                        0.42                           0.89                      0.48-1.68                      0.78                            45 (34/7)
POT1                                       1.25                       0.73-1.92                        0.33                           1.15                      0.50-2.58                      0.77                            29 (21/5)
RPS15                                     1.08                       0.62-1.87                        0.81                           2.06                      0.72-5.93                      0.11                            17 (10/5)
FBXW7                                   1.51                       0.67-3.39                        0.22                           2.19                      0.52-9.33                      0.12                             13 (9/4)
MYD88                                   0.59                       0.31-1.11                        0.19                            NA                            NA                            NA                              10 (6/0)
BIRC3                                     1.63                       0.69-3.87                        0.23                           1.29                      0.34-4.92                      0.72                              9 (6/2)
NA: not applicable due to no events in mutated patients. CI: Confidence Interval; N: number. Statistical significance in bold.
tion between treatment and NOTCH1 mutational status,
we performed an interaction-focused multivariate test.
This analysis attributed a predictive impact to NOTCH1
(P=0.05), while for all other parameters no interaction was
observed (Online Supplementary Table S4). There were no
differences in CD20 surface levels measured with flow
cytometry between subgroups defined by mutation of
NOTCH1 suggesting that differential CD20 expression is
not the cause of the lower CD20 antibody efficacy (data
not shown).
Discussion
Over recent years, in an increasing number of laborato-
ries, tNGS has replaced Sanger sequencing as a tool for
mutation analysis. The current report represents a com-
bined analysis of recurrent gene mutations studied by
tNGS with a comprehensive dataset in a large multicenter
phase III trial in CLL. In contrast to prior analyses, we used
amplicon-based tNGS which allowed sequencing of 119
exons in eight different genes with a detection limit of 5%
VAF. Although some tNGS approaches allow detection of
subclones with only 1% VAF and below,21 the aim of this
project was to evaluate the prognostic value of molecular
abnormalities for a better refinement of risk stratification.
Development of such a robust, reproducible and afford-
able assay, which can be easily adopted into a diagnostic
setup, could help in the clinical management of CLL
patients. In favor of a uniform coverage of all targets, we
trimmed sensitivity to achieve reliable results with high
specificity. Mutations with minor allelic fractions are not
detectable via Sanger sequencing and there is little evi-
dence of their clinical impact, apart from in TP53.21,22
Therefore, not surprisingly, councils like the European
Initiative for Research in CLL (ERIC) caution against deriv-
ing clinical conclusions from small subclonal mutations.23
The low number of detected minor mutations in TP53 and
other genes in COMPLEMENT1 does not allow any con-
clusions to be drawn about their prognostic significance.
However, for minor SF3B1 mutations, we found an
impact similar to mutations with VAF>10%. Further stud-
ies on clinical trials focusing on minor mutations are nec-
essary to explore the impact of such variants with a com-
prehensive validation setup. 
Our data support prior observations characterizing
SF3B1, NOTCH1, ATM and TP53 as the most frequently
mutated genes in decreasing order of frequency, while
mutations in BIRC3 and MYD88 remain very rare events
in untreated CLL.10,11  However, putting associations of
these mutations and chromosomal aberrations in a corre-
lation network uncovers two substantial associations.
First, the mutual exclusivity between del13q and +12q and
associated mutations, which is supported by prior clonal-
ity and lineage analysis showing that both aberrations are
clonal events in CLL associating with tumor pathogenesis,
but independently of each other.10 Second, intermediate
events, namely del17p and TP53 on one side and different
genomic abnormalities, mainly connected to 11q and ATM
on the other side. As these abnormalities associate with
growth advantage and accumulation in pretreated CLL,
one can envisage that either mutation of TP53 or mutation
of one of the other genes is sufficient to cause a clonal sur-
vival advantage and therefore make the respective other
event redundant. 
Besides genetic interactions, analysis of the impact on
clinical parameters, and especially on outcome after ther-
apy, was the major aim of this study. In the current COM-
PLEMENT1 data set, TP53 was the only gene mutation
associated with a decrease in PFS and OS independent of
other prognostic factors in multivariable analyses.
Notably, this correlation was observed despite the high
degree of collinearity with 17p deletion, confirming the
need of TP53 mutation testing in addition to 17p deletion
E. Tausch et al.
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Figure 2. Visualization of co-occurrence of gene mutations and genomic aberrations based on pairwise Fisher exact test. Line length corresponds to √(1/odds ratio).
Therefore, lines with a length >1 show mutual exclusivity (red) and lines with a length <1 co-occurrence (blue). Line width corresponds to stated P-value of pairwise
comparison; when P>0.1, no line is depicted. Font size characterizes incidence of mutation/aberration; green indicates association with mutated IGHV, and yellow
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diagnostics in routine practice, as recommended by cur-
rent ERIC and International Workshop on CLL (iwCLL)
guidelines.1 Accordingly, as only about half of the TP53
mutated cases harbor an additional 17p deletion, mutation
status for TP53 should be assessed in addition to del17p to
allocate patients to treatment with novel agents.
However, this subgroup accounts for just over 10% (here
11.7%) of front-line CLL cases, and does not identify all
patients with poor response and short survival times.
Therefore, the major question was whether other genetic
factors characterize aggressive CLL to the same degree. In
previous studies, this had been shown for disrupted
BIRC3, that affected the response to therapy and PFS in an
extent comparable to mutation of TP53.24 In COMPLE-
MENT1, only nine patients were mutated in BIRC3, hav-
ing an overall response rate (ORR) of 75% in contrast to
47% responders among TP53 mutated cases. While TP53
significantly shortened PFS (HR 2.02, P<0.01) and OS (HR
4.25, P<0.01), BIRC3 did not associate with either (HR
1.63 for PFS and 1.29 for OS, both not significant). The
same applies to mutations in ATM, which together with
mutations in BIRC3 associate with del11q, but do not add
any additional prognostic value to the impact of 11q on
PFS and OS in this trial. This is in contrast to data pub-
lished within the UK CLL4 trial,20 which may be explained
by a different treatment and the lack of a CD20 antibody
in UK CLL4, a different filtering approach for ATM vari-
ants, or just smaller patient numbers. However, also other
groups did not find an adverse impact of a biallelic inacti-
vation in ATM,25,26 and therefore a more comprehensive
setup with a bigger patient cohort with matched germline
samples for validation of the somatic origin of these vari-
ants is required to definitively answer this question. 
In contrast, for mutations of SF3B1, we observed a high-
er risk for early progression independently from other
prognostic factors, but this was less pronounced as com-
Gene mutations in COMPLEMENT1
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Figure 3. Kaplan-Meier estimates of progression-free survival (PFS) (left) and overall survival (OS) (right) according to the status of selected gene mutations for the
total patient cohort. Red lines: mutated (mut) subgroups; blue lines: wild-type (wt). Denoted P-values were calculated by log-rank test (mut vs. unmutated subgroup).
Table 2. Multivariate analysis based on Cox-regression for progression-free survival (PFS) / overall survival (OS).
                                                                           PFS                                                                             OS                         
Parameter present                  HR                      95%CI                     P                         HR                   95%CI                     P             N (events PFS/OS)
O-CHL arm                                   0.47                        0.35-0.61                  <0.01                       0.76                     0.44-1.29                     0.31                   183 (116/28)
TP53                                                1.71                        1.04-2.81                    0.04                        2.78                     1.17-6.62                    0.02               39 (27/16)
NOTCH1                                         1.32                        0.95-1.84                     0.10                          0.88                     0.43-1.81                     0.74                      65 (50/10)
SF3B1                                              1.52                        1.06-2.17               0.02                        1.31                      0.62-2.8                      0.48                      54 (43/11)
ATM                                                 1.02                        0.67-1.56                     0.93                          1.01                     0.43-2.38                     0.98                       45 (34/7)
POT1                                               1.28                         0.79-2.1                      0.32                          1.65                      0.62-4.4                      0.31                       29 (21/5)
RPS15                                              0.82                        0.42-1.59                     0.56                          1.16                     0.44-3.06                     0.76                       17 (10/5)
FBXW7                                            1.15                        0.58-2.29                     0.69                          1.64                     0.56-4.83                     0.37                        13 (9/4)
MYD88                                            0.72                        0.29-1.78                     0.47                           NA                           NA                            NA                          10 (6/0)
BIRC3                                             1.12                        0.47-2.66                     0.79                          0.63                     0.15-2.69                     0.53                         9 (6/2)
IGHVunmut                                         1.46                        1.09-1.95                    0.01                        1.72                     0.95-3.13                     0.08                   199 (141/44)
del17p                                            2.90                        1.49-5.67                   <0.01                       3.22                     1.18-8.76               0.02                   19 (12/10)
del11q                                            1.72                        1.19-2.51                  <0.01                       1.94                     0.98-3.83                     0.06                      58 (46/14)
NA: not applicable due to no events in mutated patients. CI: Confidence Interval; N: number. Statistical significance in bold.
pared to TP53 or del17p. These results conform to a num-
ber of previous observations.8,13,27,28 Some approaches inte-
grated SF3B1 and additional novel mutations into the hier-
archical classification for prognostication established by
Döhner in 2000.3 This is challenging as coincidences like
mutations of NOTCH1 and +12q or ATM and del11q are
not easy to resolve in these models and currently available
data are not powered to address correlations of small sub-
groups with clinical parameters. In a recent analysis,
del11q and mutations of SF3B1 and NOTCH1 were cate-
gorized as intermediate risk.29 Although del11q and SF3B1
mutation showed similar hazard ratios for PFS (1.72 and
1.52) in the multivariate analysis of COMPLEMENT1, the
former shows a trend to inferior OS (HR 1.94, P=0.06)
while SF3B1mut did not (HR 1.31, P=0.48). In addition, the
prognostic impact of NOTCH1 appeared to strongly
depend on the type of therapy (see below and
Stilgenbauer  et al.13), indicating that its use as a prognostic
marker must be approached with caution.  
As in previous genomic studies, we observed an
adverse outcome of NOTCH1mut patients on the total trial
cohort, which is more pronounced in cases with coding
mutations. However, when analyzing both treatment
arms separately, this prognostic impact turned out to be
due to differential treatment effect, i.e. it identified
NOTCH1 mutation as a predictive factor. This finding
reiterates the result obtained with rituximab, confirming
a lesser efficacy of type 1 CD20 antibodies in NOTCH1
mutated CLL13 compared to WT. The impact on PFS is
strongest in patients with a high mutant allele burden in
NOTCH1 and less pronounced in patients with minor
mutations, but can only be observed with O-CHL and not
with CHL treatment. This predictive value remains after
adding 3’UTR mutations in NOTCH1 and persisted in a
treatment interaction analysis in contrast to all other
markers. This may explain the discrepancies in previously
published data: mutation of NOTCH1 was an independ-
ent prognostic factor for PFS in heterogeneous cohorts of
patients mainly treated with CD20 antibodies as the cur-
rent standard of therapy but was not in the UK LRF CLL4
trial that did not contain CD20 antibody treat-
ment.12,14,15,30,31 Interestingly, in contrast to the previously
published relation between NOTCH1 mutation and
CD20 expression,32 NOTCH1mut cases showed no differ-
ence in CD20 surface expression as analyzed by flow
cytometry. This is in line with the results from the CLL8
trial but differs from recently published data.13,32 Even
though the underlying molecular interrelation of
NOTCH1mutations with CD20 remains unclear, the pre-
dictive impact of NOTCH1mutation is now confirmed in
two independent clinical phase III trial cohorts. Although
O-CHL shows slightly longer mPFS than CHL in
NOTCH1mut patients, it is noteworthy that both mutation
subgroups, NOTCH1mut and TP53mut, have a similar initial
impact in the setting of chemo-immunotherapy with
CD20-targeted therapy outcome (HR on PFS 1.88 for
TP53mut and 1.94 for NOTCH1mut). Moreover, the propor-
tion of patients affected by mutated NOTCH1 in the
front-line setting is bigger than the group defined by TP53
mutation. Based on current treatment guidelines, chemo-
immunotherapy is still a valuable option for a number of
patients.33 Our findings raise a note of caution on the use
of such therapy in a significant subset of CLL patients
with mutated NOTCH1. Furthermore, CD20 antibodies
remain important elements in combination with novel
compounds e.g. with venetoclax34 or ibrutinib,35 and it is
still unclear whether specific subgroups have a particular
benefit of such combinations in comparison to single
agent. The major implication from our observation is the
need to understand and circumvent the resistance against
CD20 antibodies as they remain an important element in
the treatment of CLL. Furthermore, our results underline
the role of recurrent mutations also in trials with novel
treatment principles such as BTK-, PI3K- and BCL2 inhi-
bition. 
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